Global Hypertension and Heart Failure Drugs Market Growth (Status and Outlook) 2023-2029

Global Hypertension and Heart Failure Drugs Market Growth (Status and Outlook) 2023-2029

Hypertension and Heart Failure Drugs such as β-blockers, angiotensin-converting enzyme inhibitiors, angiotensin receptor blockers, aldosterone receptor blockers, hydralazine and nitrates, which have shown mortality benefit in CHF and exert antihypertensive effects, are used as first-line agents to control HTN in CHF.

LPI (LP Information)' newest research report, the “Hypertension and Heart Failure Drugs Industry Forecast” looks at past sales and reviews total world Hypertension and Heart Failure Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Hypertension and Heart Failure Drugs sales for 2023 through 2029. With Hypertension and Heart Failure Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hypertension and Heart Failure Drugs industry.

This Insight Report provides a comprehensive analysis of the global Hypertension and Heart Failure Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hypertension and Heart Failure Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hypertension and Heart Failure Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hypertension and Heart Failure Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hypertension and Heart Failure Drugs.

The global Hypertension and Heart Failure Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Hypertension and Heart Failure Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Hypertension and Heart Failure Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Hypertension and Heart Failure Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Hypertension and Heart Failure Drugs players cover Menarini Group, Johnson & Johnson, Lupin, Boehringer Ingelheim, Novartis, Merck & Co, AstraZeneca, Pfizer, Inc and Sanofi SA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Hypertension and Heart Failure Drugs market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Diuretics
Beta Blockers
Ace Inhibitors
Alpha Blockers
Others

Segmentation by application
Men
Women

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Menarini Group
Johnson & Johnson
Lupin
Boehringer Ingelheim
Novartis
Merck & Co
AstraZeneca
Pfizer, Inc
Sanofi SA
Dr. Reddy's Laboratories
Daiichi Sankyo Company Limited

Please note: The report will take approximately 2 business days to prepare and deliver.